August 13, 2019Open Access

Identifying and targeting pathogenic PI3K/AKT/mTOR signaling in IL-6 blockade–refractory idiopathic multicentric Castleman disease

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

Castleman's Awareness & Research Effort/Castleman Disease Collaborative Network, Penn Center for Precision Medicine, University Research Foundation, Intramural NIH funding, and National Heart Lung and Blood Institute.

Preguntar a la IA

Me gusta

Guardar

Ver artículo completo

Cite This Study

Fajgenbaum et al. (Tue,) studied this question.

synapsesocial.com/papers/69d9f3401ad561c673685699 https://doi.org/https://doi.org/10.1172/jci126091

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor2002 · 1,737 citations
2mTOR Signaling in Growth, Metabolism, and Disease2017 · 7,529 citations
3Regulation of Hypoxia-Inducible Factor 1α Expression and Function by the Mammalian Target of Rapamycin2002 · 1,179 citations
4Regulation and function of ribosomal protein S6 kinase (S6K) within mTOR signalling networks2011 · 1,018 citations
5Pathogenic significance of interleukin-6 (IL-6/BSF-2) in Castleman's disease1989 · 905 citations

Preguntar a la IA

Me gusta

Guardar

Ver artículo completo